Mode
Text Size
Log in / Sign up
Phase 3 Completed N=501 Randomized Quadruple-blind Prevention

Evaluation of Vitamin D Requirements During Pregnancy

Source: ClinicalTrials.gov NCT00292591 ↗
Enrolled (actual)
501
Serious AEs
5.2%
Results posted
Aug 2016
Primary outcomePrimary: 25-Hydroxyvitamin D Concentration — 32.5; 41.0; 45.7 ng/mL
◆ Published Evidence
Highly cited
843citations · ~56 / year
Vitamin D supplementation during pregnancy: double-blind, randomized clinical trial of safety and effectiveness.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2011 · Open access · High-confidence link

Summary

The purpose of this study is to determine the effectiveness of vitamin D supplementation during pregnancy starting at the beginning of the second trimester. Mothers will be randomized to one of three vitamin D dosing groups: 400, 2,000 or 4,000 international units per day. It is hypothesized that the highest dosing regimen will result in a better vitamin D status of women regardless of their ethnicity or race.

Linked Publications (4)

  • Vitamin D supplementation during pregnancy: double-blind, randomized clinical trial of safety and effectiveness.
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2011 · 843 citations · Open access · High-confidence link
  • Vitamin D requirements and supplementation during pregnancy.
    Current opinion in endocrinology, diabetes, and obesity · 2011 · 58 citations · Open access · High-confidence link
  • Vitamin D supplementation for women during pregnancy.
    The Cochrane database of systematic reviews · 2024 · 36 citations · Open access · Likely link
  • Bone mineral density during pregnancy in women participating in a randomized controlled trial of vitamin D supplementation.
    The American journal of clinical nutrition · 2017 · 29 citations · Open access · Likely link

Outcome Measures

OutcomeResultp-value
PRIMARY
25-Hydroxyvitamin D Concentration
32.5; 41.0; 45.7

Eligibility Criteria

Inclusion Criteria

  • Women who are within the ages of 16-45 years
  • In good general health
  • Less than 12 weeks pregnant (based on last menstrual period)

Exclusion Criteria

  • Mothers with preexisting type I or type II diabetes
  • Mothers with preexisting hypertension
  • Mothers with preexisting parathyroid disease or uncontrolled thyroid disease
  • Mothers with multiple fetuses (e.g., twins, triplets, etc.)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00292591) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search